Table 3.
Transition of Antimicrobial Resistance of P. aeruginosa
| Antibiotics | Pre-Pandemic (n = 131) | Post-Pandemic (n = 185) | ||||
|---|---|---|---|---|---|---|
| R (n, %)# | I (n, %) | S (n, %) | R (n, %) | I (n, %) | S (n, %) | |
| Piperacillin/tazobactam | 18 (13.74) | 12 (9.16) | 9 (6.87) | 23 (12.43) | 2 (1.08) | 11 (5.95)** |
| Ceftazidime | 16 (12.21) | 9 (6.87) | 14 (10.69) | 24 (12.97) | 1 (0.54) | 11 (5.95)** |
| Levofloxacin | 14 (10.69) | 4 (3.05) | 21 (16.03) | 5 (2.70) | 5 (2.70) | 26 (14.05)* |
| Amikacin | 3 (2.29) | 4 (3.05) | 34 (25.95) | 2 (1.08) | 1 (0.54) | 33 (17.84) |
| Aztreonam | 21 (16.03) | 3 (2.29) | 5 (3.82) | 22 (11.89) | 5 (2.70) | 9 (4.86) |
| Imipenem | 35 (26.72) | 1 (0.76) | 3 (2.29) | 27 (14.59) | 0 (0.00) | 9 (4.86)* |
| Meropenem | 32 (24.43) | 1 (0.76) | 6 (4.58) | 22 (11.89) | 5 (2.70) | 9 (4.86) |
| Ciprofloxacin | 13 (9.92) | 8 (6.11) | 18 (13.74) | 9 (4.86) | 0 (0.00) | 27 (14.59)** |
| Gentamicin | 7 (5.34) | 14 (10.69) | 28 (21.37) | 1 (0.54) | 4 (2.16) | 31 (16.76)*** |
| Tobramycin | 4 (3.05) | 0 (0.00) | 35 (26.72) | 6 (3.24) | 0 (0.00) | 30 (16.22) |
| Cefepime | 13 (9.92) | 3 (2.29) | 18 (13.74) | 19 (10.27) | 6 (3.24) | 11 (5.95) |
Notes: S: susceptible, P. aeruginosa strain is said to be susceptible to a given antibiotic when inhibited in vitro by a concentration of this drug that is associated with a high likelihood of therapeutic success. I: intermediate: The sensitivity of a P. aeruginosa strain to a given antibiotic is said to be intermediate when it is inhibited in vitro by a concentration of this drug that is associated with an uncertain therapeutic effect. R: resistant; the P. aeruginosa strain is said to be resistant to a given antibiotic when inhibited in vitro by a concentration of this drug that is associated with a high likelihood of therapeutic failure. Pre-pandemic year: January 01, 2019-December 31, 2019; post-pandemic year: May 1, 2020-April 30, 2021. %: percentage in all P. aeruginosa isolates; *P<0.05, **P<0.01, ***P<0.001.